MPO and cystic fibrosis: Montelukast, a CysLT1 receptor antagonist, has shown some efficacy in reducing eosinophilic inflammation, improving clinical symptoms such as exercise tolerance, cough, and wheezing in people with CF, and lowering several inflammatory markers such as IL-8 and myeloperoxidase [137,138,139,140].